Rare Disease Registries in Europe - May 2019 2
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Relevant Sources for Orphan Disease Prevalence Data
16 December 2014 1 EMA/452415/2012 Rev. 1 Human Medicines Research and Development Support This document was valid from 16 December 2014 to 9 January 2018. It is no longer valid. Relevant sources for orphan disease prevalence data Sponsors applying for orphan designation for a medicine under Article 3(1) a paragraph 1 of Regulation (EC) No 141/2000 on orphan medicinal products are requested tovalid provide authoritative references to demonstrate that the condition, for which the medicine is intended, does not affect more than 5 in 10,000 people in the EU at the time the application is made. Possible sources include relevant scientific literature and databases. After more than 10 years of the implementation of the Orphan Regulation the Agency has accumulated a considerable amount of data on sources of prevalence of rare diseases from the applications for orphan designation. In most cases those sources are publicly available but not easily accessible. The Agency has decided to make the information collected so far publicly available. This will decrease the administrative burden for applicants for orphan designation and thus encourage the development of medicines for rare diseases. The information is provided in the table below will be updated regularly. The information provided herewith does not replace the obligation for the sponsor under the legislation to establish the prevalence (see Regulation (EC) No 141/2000 and the Guideline on the format and content of applications for designation as orphan medicinal product, ENTR/6283/00). Sponsors are still obliged to submit an original, up-to-date prevalence calculation supported by data with their orphan designation application. -
DATA Poster Numbers: P Da001 - 130 Application Posters: P Da001 - 041
POSTER LIST ORDERED ALPHABETICALLY BY POSTER TITLE GROUPED BY THEME/TRACK THEME/TRACK: DATA Poster numbers: P_Da001 - 130 Application posters: P_Da001 - 041 Poster EasyChair Presenting Author list Title Abstract Theme/track Topics number number author APPLICATION POSTERS WITHIN DATA THEME P_Da001 773 Benoît Carrères, Anne Benoît Carrères A systems approach to explore Microalgae are promising platforms for sustainable biofuel production. They produce triacyl-glycerides (TAG) which are easily converted into biofuel. When exposed to nitrogen limitation, Data/ Application Klok, Maria Suarez Diez, triacylglycerol production in Neochloris Neochloris oleoabundans accumulates up to 40% of its dry weight in TAG. However, a feasible production requires a decrease of production costs, which can be partially reached by Application Lenny de Jaeger, Mark oleoabundans increasing TAG yield.We built a constraint-based model describing primary metabolism of N. oleoabundans. It was grown in combinations of light absorption and nitrate supply rates and the poster Sturme, Packo Lamers, parameters needed for modeling of metabolism were measured. Fluxes were then calculated by flux balance analysis. cDNA samples of 16 experimental conditions were sequenced, Rene' Wijffels, Vitor Dos assembled and functionally annotated. Relative expression changes and relative flux changes for all reactions in the model were compared.The model predicts a maximum TAG yield on light Santos, Peter Schaap of 1.07g (mol photons)-1, more than 3 times current yield under optimal conditions. Furthermore, from optimization scenarios we concluded that increasing light efficiency has much higher and Dirk Martens potential to increase TAG yield than blocking entire pathways.Certain reaction expression patterns suggested an interdependence of the response to nitrogen and light supply. -
Genetic Determinants Underlying Rare Diseases Identified Using Next-Generation Sequencing Technologies
Western University Scholarship@Western Electronic Thesis and Dissertation Repository 8-2-2018 1:30 PM Genetic determinants underlying rare diseases identified using next-generation sequencing technologies Rosettia Ho The University of Western Ontario Supervisor Hegele, Robert A. The University of Western Ontario Graduate Program in Biochemistry A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Science © Rosettia Ho 2018 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Medical Genetics Commons Recommended Citation Ho, Rosettia, "Genetic determinants underlying rare diseases identified using next-generation sequencing technologies" (2018). Electronic Thesis and Dissertation Repository. 5497. https://ir.lib.uwo.ca/etd/5497 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Rare disorders affect less than one in 2000 individuals, placing a huge burden on individuals, families and the health care system. Gene discovery is the starting point in understanding the molecular mechanisms underlying these diseases. The advent of next- generation sequencing has accelerated discovery of disease-causing genetic variants and is showing numerous benefits for research and medicine. I describe the application of next-generation sequencing, namely LipidSeq™ ‒ a targeted resequencing panel for the identification of dyslipidemia-associated variants ‒ and whole-exome sequencing, to identify genetic determinants of several rare diseases. Utilization of next-generation sequencing plus associated bioinformatics led to the discovery of disease-associated variants for 71 patients with lipodystrophy, two with early-onset obesity, and families with brachydactyly, cerebral atrophy, microcephaly-ichthyosis, and widow’s peak syndrome. -
RD-Action Matchmaker – Summary of Disease Expertise Recorded Under
Summary of disease expertise recorded via RD-ACTION Matchmaker under each Thematic Grouping and EURORDIS Members’ Thematic Grouping Thematic Reported expertise of those completing the EURORDIS Member perspectives on Grouping matchmaker under each heading Grouping RD Thematically Rare Bone Achondroplasia/Hypochondroplasia Achondroplasia Amelia skeletal dysplasia’s including Achondroplasia/Growth hormone cleidocranial dysostosis, arthrogryposis deficiency/MPS/Turner Brachydactyly chondrodysplasia punctate Fibrous dysplasia of bone Collagenopathy and oncologic disease such as Fibrodysplasia ossificans progressive Li-Fraumeni syndrome Osteogenesis imperfecta Congenital hand and fore-foot conditions Sterno Costo Clavicular Hyperostosis Disorders of Sex Development Duchenne Muscular Dystrophy Ehlers –Danlos syndrome Fibrodysplasia Ossificans Progressiva Growth disorders Hypoparathyroidism Hypophosphatemic rickets & Nutritional Rickets Hypophosphatasia Jeune’s syndrome Limb reduction defects Madelung disease Metabolic Osteoporosis Multiple Hereditary Exostoses Osteogenesis imperfecta Osteoporosis Paediatric Osteoporosis Paget’s disease Phocomelia Pseudohypoparathyroidism Radial dysplasia Skeletal dysplasia Thanatophoric dwarfism Ulna dysplasia Rare Cancer and Adrenocortical tumours Acute monoblastic leukaemia Tumours Carcinoid tumours Brain tumour Craniopharyngioma Colon cancer, familial nonpolyposis Embryonal tumours of CNS Craniopharyngioma Ependymoma Desmoid disease Epithelial thymic tumours in -
The Epidemiology of Listeriosis in Pregnant
Jeffs et al. BMC Public Health (2020) 20:116 https://doi.org/10.1186/s12889-020-8221-z RESEARCH ARTICLE Open Access The epidemiology of listeriosis in pregnant women and children in New Zealand from 1997 to 2016: an observational study Emma Jeffs1, Jonathan Williman2, Cheryl Brunton2, Joanna Gullam3 and Tony Walls1* Abstract Background: Listeria monocytogenes causes the foodborne infection listeriosis. Pregnant women, infants and immunocompromised children are at increased risk for infection. The aim of this study was to describe the trends in the epidemiology of disease notifications and hospital admissions due to listeriosis in pregnant women aged 15 to 45 years and children aged less than 15 years in New Zealand (NZ) from 1997 to 2016. Methods: In this population-based descriptive study, listeriosis notification and hospitalization rates from 1997 to 2016 were analyzed. Notification data were extracted from the Institute of Environmental Science and Research (ESR) Notifiable Diseases Database (EpiSurv) and hospitalization data were extracted from the National Minimum Dataset (NMDS). Pregnant women aged 15 to 45 years and children less than 15 years of age were included. Subgroup analysis was conducted for age and ethnicity. Outcomes of infection were described. Results: In the 20-year period considered, there were 147 pregnancy-associated cases of listeriosis either notified to ESR (n = 106) and/or coded in the NMDS (n = 99), giving a crude incidence rate of 12.3 (95% CI 10.4, 14.4) per 100, 000 births. In addition, there were 22 cases in children aged 28 days to < 15 years (incidence =0.12, 95% CI 0.08 to 0.19 per 100,000). -
Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y. -
Orphanet Report Series Rare Diseases Collection
Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic -
Download File
Freely available online Conference Proceedings Proceedings of the Ninth International Meeting on Neuroacanthocytosis Syndromes 1 1,2,3 Editors: Kevin Peikert & Andreas Hermann 1 Department of Neurology, University Hospital Carl Gustav Carus, Technische Universita¨t Dresden, Dresden, Germany, 2 Center for Regenerative Therapies Dresden (CRTD), Technische Universita¨t Dresden, Dresden, Germany, 3 German Center for Neurodegenerative Diseases (DZNE) Dresden, Dresden, Germany Citation: Peikert K, Hermann A, editors. Proceedings of the ninth international meeting on neuroacanthocytosis syndromes; 2018 March 23–25; Dresden, Germany. Tremor Other Hyperkinet Mov. 2018; 8. doi: 10.7916/D8ZC9KCW Published: July 17, 2018 Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed. Introduction its genetic basis in 2001. In spite of the wealth of in vivo and in The 9th International Meeting on Neuroacanthocytosis Syndromes vitro models presented at neuroacanthocytosis symposia past and was held on March 23th–25th, 2018 in Dresden, Germany. The present, its function (or functions) has so far remained elusive. conference followed the tradition of the previous eight international It may be worthwhile to review features of the disease for clues. symposia, the last of which was held in Ann Arbor, USA in May, 2016. 1) ChAc is an autosomal-recessive condition. 2) Gender distribution Following the positive response to the previous meeting, a major appears equal. -
Rainbows Basic Symptom Control in Paediatric Palliative Care
Ninth edition, 2013 Basic Symptom Control in Paediatric Palliative Care The Rainbows Children’s Hospice Guidelines www.togetherforshortlives.org.uk Basic Symptom Control in Paediatric Palliative Care The Rainbows Children’s Hospice Guidelines Ninth Edition, 2013 ISBN: 1 898447284 Basic Symptom Control in Paediatric Palliative Care © Dr Satbir Singh Jassal Formulary © The Association for Paediatric Palliative Medicine (APPM), March 2012 The formulary is due for revision at the end of 2014 Author: Dr Satbir Singh Jassal B.Med Sci, B.M., B.S., DRCOG, Dip Pall Med, DFSRH, MRCGP, FRCPCH (Hon), Medical Director Rainbows Children’s Hospice and General Practitioner Production: Myra Johnson and Katrina Kelly, Together for Short Lives Design: Qube Design Associates Ltd Certified by the Information Standard Together for Short Lives is the leading UK charity that speaks for all children with life-threatening and life-limiting conditions and all those who support, love and care for them. When children are unlikely to reach adulthood, we aim to make a lifetime of difference for them and their families. Together for Short Lives 4th Floor, 48-52 Bridge House, Baldwin Street, Bristol BS1 1QB T: 0117 989 7820 [email protected] www.togetherforshortlives.org.uk Together for Short Lives is a registered charity in England and Wales (1144022) and Scotland (SC044139) and a company limited by guarantee (7783702) Disclaimer: Although Together for Short Lives has taken care to ensure that the contents of this document are correct and up to date at the time of publishing, the information contained in the document is intended for general use only. -
Neuropathy in Childhood Mitochondrial Disease, Including Riboflavin Transporter Deficiency: Phenotype, Neurophysiology and Disease-Modifying Therapy in a Recently Described Treatable
COPYRIGHT AND USE OF THIS THESIS This thesis must be used in accordance with the provisions of the Copyright Act 1968. Reproduction of material protected by copyright may be an infringement of copyright and copyright owners may be entitled to take legal action against persons who infringe their copyright. Section 51 (2) of the Copyright Act permits an authorized officer of a university library or archives to provide a copy (by communication or otherwise) of an unpublished thesis kept in the library or archives, to a person who satisfies the authorized officer that he or she requires the reproduction for the purposes of research or study. The Copyright Act grants the creator of a work a number of moral rights, specifically the right of attribution, the right against false attribution and the right of integrity. You may infringe the author’s moral rights if you: - fail to acknowledge the author of this thesis if you quote sections from the work - attribute this thesis to another author - subject this thesis to derogatory treatment which may prejudice the author’s reputation For further information contact the University’s Copyright Service. sydney.edu.au/copyright Neuropathy in childhood mitochondrial disease, including riboflavin transporter deficiency: phenotype, neurophysiology and disease-modifying therapy in a recently described treatable disorder Dr Manoj Peter Menezes A thesis submitted for the degree of Doctor of Philosophy in the faculty of Medicine, The University of Sydney, 2015. Submitted October 2015 1 DECLARATION I hereby declare that this submission is my own work and that, to the best of my knowledge and belief, it contains no material previously published or written by another person or material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement has been made in the text. -
Machine Learning Based Psychological Disease Support Model Assisting Psychoanalysts and Individuals in Clinical Decision Ministration
International Journal of Computing and Digital Systems ISSN (2210-142X) Int. J. Com. Dig. Sys. 9, No.4 (July-2020) http://dx.doi.org/10.12785/ijcds/090414 Machine Learning Based Psychological Disease Support Model Assisting Psychoanalysts and Individuals in Clinical Decision Ministration Vikas Kamra1, Praveen Kumar2 and Masoud Mohammadian3 1Research Scholar, Amity University Uttar Pradesh, Noida, India 2CSE Department, Amity University Uttar Pradesh, Noida, India 3Faculty of Science and Technology, University of Canberra, Australia Received 11 Oct.2019, Revised 9 Mar. 2020, Accepted 11 May 2020, Published 1 Jul. 2020 Abstract: Mental Pressure is a significant contributor to an individual's health and is directly linked with various diseases including depression and mental disorder. It is therefore extremely important to monitor the patient's misbehavior. Therapeutic-psychology based on machine learning algorithms clearly concentrates on studying multifaceted datasets to deduce statistical features in order to create generalized projections about patients. A novel paradigm to develop Psychological Disease Support Model (PDSM) will be discussed through this research paper. This model will support diagnosis of various psychological diseases like schizophrenia, bipolar disorder and obsessive compulsive disorder. It will take some health parameters as input from end user, process that data based on machine learning approach and provides desired outcome in user friendly way. Existing methods of wellness surveillance continue to confront many difficulties owing to inadequate information from healthcare records. The proposed approach seeks to develop a scheme of autonomous choice assistance for an initial treatment of important psychological occurrences. Machine based learning is widely described as a methodology that automatically knows how to solve the issue optimally, instead of being programmed by natural beings in order to provide a set answer. -
Orphanet Report Series Rare Diseases Collection
Orphanet Report Series Rare Diseases collection January 2013 Disease Registries in Europe www.orpha.net 20102206 Table of contents Methodology 3 List of rare diseases that are covered by the listed registries 4 Summary 13 1- Distribution of registries by country 13 2- Distribution of registries by coverage 14 3- Distribution of registries by affiliation 14 Distribution of registries by country 15 European registries 38 International registries 41 Orphanet Report Series - Disease Registries in Europe - January 2013 2 http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf Methodology Patient registries and databases constitute key instruments to develop clinical research in the field of rare diseases (RD), to improve patient care and healthcare planning. They are the only way to pool data in order to achieve a sufficient sample size for epidemiological and/or clinical research. They are vital to assess the feasibility of clinical trials, to facilitate the planning of appropriate clinical trials and to support the enrolment of patients. Registries of patients treated with orphan drugs are particularly relevant as they allow the gathering of evidence on the effectiveness of the treatment and on its possible side effects, keeping in mind that marketing authorisation is usually granted at a time when evidence is still limited although already somewhat convincing. This report gather the information collected by Orphanet so far, regarding systematic collections of data for a specific disease or a group of diseases. Cancer registries are listed only if they belong to the network RARECARE or focus on a rare form of cancer. The report includes data about EU countries and surrounding countries participating to the Orphanet consortium.